TARS实时信号 | 通过Getagraph.com最大化利润

出售 117532 min ago

@ $29.83

发出时间: 14 Feb 2024 @ 00:42

回报率: 23.53%

上一信号: Feb 9 - 22:30

上一信号: 购买

回报率: -3.38 %

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions...

Stats
今日成交量	652 217
平均成交量	697 548
市值	1.38B
EPS	$0 ( 2024-02-27 )
下一个收益日期	( $0 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.98
ATR14	$0.0780 (0.21%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Mottiwala Aziz	Buy	12 938	Common Stock
2024-03-18	Mottiwala Aziz	Sell	4 766	Common Stock
2024-03-15	Mottiwala Aziz	Sell	8 148	Restricted Stock Units
2024-03-15	Mottiwala Aziz	Sell	4 790	Restricted Stock Units
2024-03-15	Wahl Bryan	Buy	12 038	Common Stock

INSIDER POWER
31.25
Last 100 transactions
Buy: 1 038 524 \| Sell: 656 594

音量相关性

長: 0.33 (neutral)

短: -0.65 (weak negative)

Signal:(63.364) Neutral

Tarsus Pharmaceuticals, 相关性

10 最正相关
NVCN	0.951
AGNCP	0.949
SILK	0.943
VCEL	0.941
ADTH	0.94
TIOAU	0.936
ROVR	0.935
TIOA	0.935
BRIVU	0.931
INBK	0.93

10 最负相关
CRCT	-0.945
SGML	-0.943
VRM	-0.942
OSTK	-0.94
TBLT	-0.94
IRBT	-0.939
MYMD	-0.939
SNAX	-0.939
REVB	-0.936
TENX	-0.931

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Tarsus Pharmaceuticals, 相关性 - 货币/商品

0.54
( weak )

0.77
( moderate )

-0.75
( moderate negative )

0.74
( moderate )

0.55
( weak )

Tarsus Pharmaceuticals, 财务报表

Annual	2023
营收:	$17.45M
毛利润:	$15.85M (90.87 %)
EPS:	$-4.62

FY	2023
营收:	$17.45M
毛利润:	$15.85M (90.87 %)
EPS:	$-4.62

FY	2022
营收:	$25.82M
毛利润:	$24.86M (96.30 %)
EPS:	$-2.52

FY	2021
营收:	$57.03M
毛利润:	$57.03M (100.00 %)
EPS:	$-0.00200

Financial Reports:

No articles found.

Tarsus Pharmaceuticals,

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

实时更新： Tarsus Pharmaceuticals, [TARS]

Upcoming Earnings Alert